Introduction: Atopic dermatitis is the most common chronic inflammatory skin disease with
high prevalence rates in adults and even higher among children. For the numerous patients …

Purpose of review Atopic dermatitis (AD) is a common chronic inflammatory relapsing skin
disease that greatly affects the quality of life of patients and their relatives. Topical treatment …

Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases. The
prevalence of AD is increasing and is currently estimated at 10–20% in adults worldwide. In …

Background Clinical trial data for dupilumab, a monoclonal antibody against the interleukin‐
4 receptor (IL‐4Rα), have shown that it is safe and effective for the treatment of moderate to …

Atopic dermatitis (AD) is a common, chronic, inflammatory skin disorder with high physical
and emotional burden. AD usually starts in early childhood and has a heterogeneous …

Atopic dermatitis (AD) is a chronic inflammatory condition that affects 5–10% of adults and 9–
18% of children and its pathology is rooted in the Th-2-mediated immune response …

Atopic dermatitis (AD) is a common inflammatory skin disorder that manifests as eczematous
lesions, often associated with allergic rhinitis and asthma. Historically, moderate-to-severe …

Introduction: Current treatment options for moderate-to-severe atopic dermatitis (AD) are
limited and have potentially dangerous side effects. Dupilumab is a novel monoclonal …

Introduction: Atopic dermatitis (AD) is a recurrent, pruritic inflammatory skin disease with
complex immunopathogenesis characterized by a dominant TH2 response. Dupilumab is an …

Introduction: Atopic dermatitis is a common inflammatory skin disease with an increasing
prevalence. Treatment of patients suffering from mild or moderate disease includes the use …